You should not place undue reliance on any forward-looking statements, which speak only as of the date on which they are made. enGene anticipates that subsequent events and developments will cause enGene's assessments to change. While enGene may elect to update these forward-looking statements at some point in the future, enGene specifically disclaims any obligation to do so, unless required by applicable law. Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved.

 
 
                         enGene Holdings Inc. 
     Condensed Consolidated Statements of Operations Information 
                             (unaudited) 
    (Amounts in thousands of USD, except share and per share data) 
 
                                              Year Ended October 31, 
                                            -------------------------- 
                                                 2024          2023 
                                            ---------------  --------- 
Operating expenses: 
    Research and development                $        38,315  $  16,458 
    General and administrative                       23,982      9,602 
                                                -----------   -------- 
        Total operating expenses                     62,297     26,060 
                                                -----------   -------- 
Loss from operations                                 62,297     26,060 
Total other (income) expense, net                   (7,136)     73,840 
                                                -----------   -------- 
  Net loss before provision for income tax           55,161     99,900 
    Provision for (benefit from) income 
     taxes                                             (19)         17 
                                                -----------   -------- 
Net loss                                    $        55,142  $  99,917 
  Deemed dividend attributable to 
   redeemable convertible preferred 
   shareholders                                          --      4,822 
                                                -----------   -------- 
Net loss attributable to common 
 shareholders, basic and diluted                     55,142    104,739 
Weighted-average common shares 
 outstanding, basic and diluted                  37,782,346    692,609 
                                                -----------   -------- 
Net loss per share of common shares, basic 
 and diluted                                $          1.46  $  151.22 
                                                ===========   ======== 
 
 
 
                      enGene Holdings Inc. 
        Condensed Consolidated Balance Sheet Information 
                           (unaudited) 
                  (Amounts in thousands of USD) 
 
                                     October 31,     October 31, 
                                         2024            2023 
                                    --------------  ------------- 
Cash and cash equivalents           $      173,004  $      81,521 
Total assets                               311,173         86,959 
Total liabilities                           38,561         14,473 
Total shareholders' equity                 272,612         72,486 
 

View source version on businesswire.com: https://www.businesswire.com/news/home/20241219627723/en/

 
    CONTACT:    For media contact: media@engene.com 

For investor contact: investors@engene.com

(END) Dow Jones Newswires

December 19, 2024 16:05 ET (21:05 GMT)